A New Step in Health

In our modern world, we are almost constantly bombarded with different ideas and discoveries in health products, and theories on how to become healthier. We are finally discovering the causes for many of our health problems that we have faced for years, which has required us to create products and solutions to overcome these problems and improve our lives. While we might have addressed plenty of health related issues, there are still so many we have yet to develop fully. So what is the next step? Captozyme believes that there is more we can do in products and procedures to help improve our health and therefore humankind, and is working to achieve exactly that. Captozyme is a researching company that focuses primarily on anti-nutrients such as oxalate, and developing enzyme products for people with hyperoxaluria and kidney stones.

Hyperoxaluria means that a person has increased urine oxalate, which can cause formation of calcium oxalate, the primary component of most kidney stones. These oxalates can be found in a variety of products that we commonly ingest on a daily basis, and therefore are often unknowingly dangerous to those with hyperoxaluria. At Captozyme we strive to develop ways to administer more of our enzymes in order to decrease the build-up of oxalate, and as a result, assist kidney stone formers in leading healthier lives.

Captozyme Accepted to the NIH Commercialization Accelerator Program (CAP)

The NIH Commercialization Accelerator Program (CAP) is designed to help some of the agency’s most promising small life science and healthcare Phase II grantees develop their commercial businesses and transition their SBIR/STTR-funded technologies into the marketplace. Applicants are selected via a competitive process for a limited number of slots in the program.

See more information here: https://sbir.nih.gov/cap

Diet for Kidney Stone Prevention

Kidney stones can form when substances in the urine—such as calcium, oxalate, and phosphorus—become highly concentrated. Diet is one of several factors that can promote or inhibit kidney stone formation. Certain foods may promote stone formation in people who are susceptible, but scientists do not believe that eating any specific food causes stones to form in people who are not susceptible. Other factors that affect kidney stone formation include genes, environment, body weight, and fluid intake. 

Read more here: http://www.niddk.nih.gov/health-information/health-topics/urologic-disease/diet-for-kidney-stone-prevention/Pages/facts.aspx

Visit by Governor Rick Scott

Governor Rick Scott awarded Aaron and Helena Cowley the Young Entrepreneur Award for their work building Captozyme.  Aaron and Helena were among seven young business leaders to receive the award. 

About 40 people attended the event in the Innovation Hub in Gainesville; the Governor took a tour of the incubator with the entrepreneurs before presenting the award and addressing the media.

12th Annual BioFlorida Celebration of Technology

Thursday, May 7th 2015                                                                                          



Interested in hearing about our ongoing and upcoming projects?  

Join us along with many other vendors in attending the 12th annual BioFlorida Celebration of Biotechnology at Progress Corporate Park in Alachua, FL.

           Location:  RTI Surgical, Alachua, FL

Event Time: 9:30am-1:00pm



Partner Visit, Wuhan, China


January, 2015

Partner Visit, Wuhan, China

Captozyme's management team will visit Wuhan “Optics Valley” to further explore business relationships. “Optics Valley” or Donghu New Technology Development Zone is one of the Technology Development Zones in China, located in the east of Wuchang District in Wuhan.  In 2011 it was designated as a New Technology Development Zone for Optical Technology, and since then been self-labeled as the “Optics Valley” of China.

Edwards Wildman LLP Admits Captozyme into HIT Program

Edwards Wildman LLP has approved Captozyme LLC into the Firm's Helping Innovators Thrive  (HIT) program.  The Firm only admits early stage companies that propose innovative technologies or business concepts into its HIT program.  The acceptance into the HIT program will provide Captozyme with non-standard billing arrangements tailored to its needs.